Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1-2, Multicenter, Open-Label Study of The X-Linked Inhibitor of Apoptosis (XIAP) Antisense AEG35156 Given in Combination With Gemcitabine in Patients With Advanced Pancreatic Cancer

NCT00557596 is registered in ClinicalTrials.gov with Aegera Therapeutics as lead sponsor.

NCT NCT00557596
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00557596 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1-2, Multicenter, Open-Label Study of The X-Linked Inhibitor of Apoptosis (XIAP) Antisense AEG35156 Given in Combination With Gemcitabine in Patients With Advanced Pancreatic Cancer
Lead sponsor
Aegera Therapeutics
Phase
Phase 1/2
Overall status
Terminated
Start date
September 30, 2007
Completion date
November 30, 2009
Enrollment
48 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoma, pancreas